Metis Global Partners LLC Has $1.21 Million Position in Insulet Corporation $PODD

Metis Global Partners LLC grew its holdings in Insulet Corporation (NASDAQ:PODD) by 6.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,842 shares of the medical instruments supplier’s stock after purchasing an additional 230 shares during the quarter. Metis Global Partners LLC’s holdings in Insulet were worth $1,207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in PODD. Larson Financial Group LLC increased its holdings in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet during the 1st quarter worth approximately $26,000. SouthState Corp grew its position in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the period. Kozak & Associates Inc. bought a new stake in shares of Insulet in the 2nd quarter valued at $32,000. Finally, Golden State Wealth Management LLC lifted its position in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 69 shares during the period.

Insulet Trading Up 1.9%

NASDAQ:PODD opened at $326.28 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a one year low of $230.05 and a one year high of $353.50. The company has a market cap of $22.97 billion, a PE ratio of 99.17, a PEG ratio of 2.64 and a beta of 1.39. The firm has a 50-day moving average of $324.30 and a 200-day moving average of $311.20.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PODD shares. Sanford C. Bernstein increased their target price on shares of Insulet from $400.00 to $410.00 in a research note on Friday, November 7th. The Goldman Sachs Group lifted their price target on shares of Insulet from $375.00 to $388.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Stifel Nicolaus assumed coverage on shares of Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Finally, Piper Sandler upped their price target on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average target price of $374.10.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.